Unraveling the genetics of glaucoma
June 16, 2021
Details enhance knowledge of biological pathways that contribute to disease pathogenesis.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Gene Therapy
Targeting human retinal progenitor cell injections for RP
June 18, 2021
Investigators find approach improved vision and visual fields in some patients.
Investigators start pivotal subretinal gene therapy trial
June 11, 2021
RGX-314 eyed by investigators as a therapeutic option for exudative AMD.
Optogenetic gene therapy restores vision in 11 RP patients
June 03, 2021
Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.
Oyster Point Pharma unveils preclinical study results for Enriched Tear Film Gene Therapy to target ocular surface diseases
June 03, 2021
According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.
Single injection maintenance
May 29, 2021
ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.
Results unveiled from phase 2/3 gene therapy study for XLRP
May 14, 2021
While Biogen’s XIRIUS study did not meet its primary endpoint of demonstrating a statistically significant improvement in treated eyes, positive trends were observed across several clinically relevant prespecified secondary endpoints.
The first steps in gene therapy for achromatopsia
May 14, 2021
Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.
Gene therapy prompts foveal morphologic changes in LCA
May 10, 2021
Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
X-linked retinitis pigmentosa Phase 1/2 clinical trial provides positive 12-month data
May 06, 2021
According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.